Biotech Values

[DewDiligence]

QURE +52% PM on gene-therapy collaboration with BMY and equity purchase:

http://www.wsj.com/articles/bristol-myers-invests-in-uniqure-in-heart-disease-pact-1428322868

Bristol-Myers Squibb Co. agreed to invest in the Dutch company, UniQure NV and work together on gene therapies for cardiovascular disease.

Bristol-Myers will have exclusive access to the Dutch company’s proprietary gene therapy program for congestive heart failure. The two companies will collaborate on 10 targets in total and may work on future projects in other disease areas.

Bristol-Myers will pay about $100 million. This includes an upfront payment of $50 million, a $15 million payment for selecting two collaboration targets, and a $32 investment in UniQure that represents a 4.9% stake in the company. Bristol-Myers will acquire an additional 5% ownership before the end of the year at a 10% premium.

UniQure can receive at least an additional $254 million if certain milestones are reached. It is also eligible for $217 million for other gene therapy products.

…UniQure will make supplies using its insect-cell based manufacturing platform. Bristol-Myers will pay for research and development costs as well as lead development and commercialization.

The companies own joint PR:
http://news.bms.com/press-release/rd-news/bristol-myers-squibb-and-uniqure-enter-exclusive-strategic-collaboration-devel